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Abstract
Background—Neuroactive steroids modulate ethanol intake in several self-administration
models with variable effects. The purpose of this work was to examine the effects of the long-
acting synthetic GABAergic neurosteroid ganaxalone and the endogenous neurosteroid
pregnenolone, a precursor of all GABAergic neuroactive steroids, on the maintenance of ethanol
self-administration in an animal model of elevated drinking – the alcohol preferring (P) rats.
Methods—P rats were trained to self-administer ethanol (15% v/v) vs. water on a concurrent
schedule of reinforcement, and the effects of ganaxolone (0 – 30 mg/kg, SC) and pregnenolone (0
– 75 mg/kg, IP) were evaluated on the maintenance of ethanol self-administration. After
completion of self-administration testing, doses of the neuroactive steroids that altered ethanol
self-administration were assessed on spontaneous locomotor activity. Finally, the effect of
pregnenolone administration on cerebral cortical levels of the GABAergic neuroactive steroid (3α,
5α)-3-hydroxypregnan-20-one (allopregnanolone, 3α,5α-THP) was determined in both ethanol
experienced and inexperienced P rats since pregnenolone is a precursor of these steroids.
Results—Ganaxolone produced a dose-dependent biphasic effect on ethanol reinforcement, as
the lowest dose (1 mg/kg) increased and the highest dose (30 mg/kg) decreased ethanol-reinforced
responding. However, the highest ganaxolone dose also produced a nonspecific reduction in
locomotor activity. Pregnenolone treatment significantly reduced ethanol self-administration (50
and 75 mg/kg), without altering locomotor activity. Pregnenolone (50 mg/kg) produced a
significant increase in cerebral cortical allopregnanolone levels. This increase was observed in the
self-administration trained animals, but not in ethanol naïve P rats.
Conclusions—These results indicate that pregnenolone dose-dependently reduces operant
ethanol self-administration in P rats without locomotor impairment, suggesting it may have
potential as a novel therapeutic for reducing chronic alcohol drinking in individuals that abuse
alcohol.
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GABAergic neuroactive steroids are endogenous neuromodulators derived primarily from
progesterone ((3α,5α)-3-hydroxypregnan-20-one, allopregnanolone) and
deoxycorticosterone ((3α,5α)-3,21-dihydroxypregnan-20-one,
tetrahydrodeoxycorticosterone) that have nanomolar potency at GABAA receptors ((Morrow
et al., 1987), see (Paul and Purdy, 1992), for review). These steroids produce anxiolytic,
sedative-hypnotic, anticonvulsant and cognitive impairing effects when administered to
rodents (see (Kumar et al., 2009), for review), and may also contribute to the behavioral
effects of ethanol in rats, since ethanol increases plasma and brain levels of these steroids
(Barbaccia et al., 1999; Morrow et al., 1999; Porcu et al., 2009; VanDoren et al., 2000).
Indeed, blockade of ethanol-induced increases in neuroactive steroids using the steroid 5α-
reductase inhibitor finasteride attenuates behavioral effects of ethanol in rodents (Hirani et
al., 2002; Hirani et al., 2005; Khisti et al., 2003; Matthews et al., 2002; Morrow et al., 2001;
VanDoren et al., 2000) and subjective effects of ethanol in humans (Pierucci-Lagha et al.,
2005).
Several previous studies have explored whether systemic administration of the endogenous
or synthetic GABAergic neuroactive steroids alters ethanol drinking behavior in rodents.
Studies in non-dependent rats have shown that pretreatment with a 3 mg/kg dose of
allopregnanolone, but not a 1 or 10 mg/kg dose, increases oral self-administration of ethanol
(Janak et al., 1998). Similar studies in male C57BL/6J mice showed that allopregnanolone
dose-dependently modulated ethanol intake during a two hour session, with low doses (3.2
mg/kg) increasing ethanol consumption and high doses (24 mg/kg) decreasing ethanol
consumption (Ford et al., 2005b). The presence of ethanol dependence may influence these
effects, since an identical dose of allopregnanolone (5mg/kg) can increase ethanol self-
administration in non-dependent ethanol-preferring P rats while decreasing ethanol
administration in ethanol-dependent P rats (Morrow et al., 2001). This may indicate a
complex relationship where low dose neuroactive steroids promote drinking in non-
dependent animals consuming small amounts of ethanol, while preventing heavy drinking
by dependent P rats. Moreover, high doses of allopregnanolone suppress drinking in non-
dependent animals (Ford et al., 2005b).
Allopregnanolone administered systemically is rapidly metabolized in vivo (Purdy et al.,
1990), therefore it may be important to use longer acting neuroactive steroids for studies of
ethanol self-administration sessions lasting longer than 20 minutes. Short acting compounds
may produce a withdrawal state during the testing period that could confound the
interpretation of the data. Indeed, the non-hydrolysable, long-acting GABAergic neuroactive
steroid 3α,5β-20- oxo-pregnane-3-carboxylic acid dose-dependently reduces operant
ethanol-self administration in rats (O’Dell et al., 2005). However, these prior studies did not
control for potential effects on locomotor activity that could have influenced the results.
Thus, further studies are needed to determine if GABAergic neuroactive steroids reduce
excessive drinking in animal models of alcoholism.
Another approach to investigating the role of neuroactive steroids in alcohol drinking
involves the administration of the 5α-reductase inhibitor finasteride. Finasteride has been
shown to reduce basal and ethanol-induced increases in GABAergic neuroactive steroids
(Moran and Smith, 1998; VanDoren et al., 2000). Finasteride administration can reduce
ethanol consumption when administered 24 hrs prior to testing of ethanol consumption
(Ford et al., 2005a; Ford et al., 2008b). However, the interpretation of these results is
complex because finasteride increases pregnenolone and progesterone levels, while reducing
allopregnanolone levels (Ford et al., 2008b). In addition, progesterone can be converted to
another GABAergic neuroactive steroid, (3α)-3-hydroxy-4-pregnen-20-one, that is present
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in rat brain (Griffin and Mellon, 2001) and has potent actions on GABAA receptors
(Morrow et al., 1990).
The purpose of this study was to further clarify the role of neuroactive steroids in ethanol
drinking by testing the effects of ganaxolone and pregnenolone on operant ethanol self-
administration and locomotor activity in non-dependent alcohol-preferring (P) rats.
Ganaxolone ((3α,3β,5α)-3-hydroxy-3-methyl-5-pregnan-20-one) is a synthetic GABAergic
neuroactive steroid that differs from allopregnanolone only by the addition of the 3β-methyl
group on C3 that prevents the metabolism of the compound, increasing the half life by hours
(Carter et al., 1997). Investigation of the effect of ganaxolone addresses whether the
biphasic effects of allopregnanolone on ethanol drinking are related to the rapid metabolism
of this compound in vivo. Pregnenolone was investigated since it is the precursor of several
endogenous GABAergic neuroactive steroids, including allopregnanolone (3α,5α-THP),
pregnanolone (3α,5β-THP), tetrahydrodeoxycorticosterone (3α,5α-THDOC) and (3α3-
hydroxy-4-pregnen-20- one, and has previously been shown to increase the concentrations
of allopregnanolone and pregnanolone in rats and humans (Marx et al., 2009; Porcu et al.,
2009). We examined the effects of ganaxolone and pregnenolone on ethanol reinforcement
in P rats, a prominent genetic model of high alcohol intake (Lumeng et al., 1977; Murphy et
al., 2002). The P rat line has been found to fulfill the requirements of an animal model of
alcoholism (Lester and Freed, 1973), as these rats voluntarily consume alcohol in quantities
that produce significant blood alcohol concentrations, develop tolerance and dependence
through voluntary drinking (Kampov-Polevoy et al., 2000; Lumeng and Li, 1986; Murphy et
al., 2002) and maintain preference for ethanol when palatable solutions are presented as an
alternative (Lankford et al., 1991).
Methods
Subjects
Male ethanol-preferring inbred P (P) rats (n=16) were derived from a line provided by
Indiana University. This stock of P rats (5B substrain) was derived from breeders of the
selected line of P rats originally provided in 1999 to the Bowles Center for Alcohol Studies
(courtesy of Dr. T.K. Li) and has been bred on-site at the University of North Carolina at
Chapel Hill. These rats weighed 505.8 ±12.6 g (mean ± S.E.M.) at the beginning of testing
and had access to food and water ad libitum unless specified otherwise. The rats were pair-
housed in Plexiglas cages in a colony room maintained on a 12-h light/dark cycle. All
experiments were performed during the light portion of this cycle. All procedures were
carried out in accordance with the “Guide for the Care and Use of Laboratory Animals”
(National Research Council, National Academy Press, 1996) and institutional guidelines.
Apparatus
The self-administration chambers (30.5 × 24.1 × 21.0 cm; Med Associates, Georgia, VT)
were kept within sound attenuating cubicles, each equipped with its own exhaust fan to
mask external sound and provide ventilation. The left and right wall of each chamber
contained one liquid receptacle and a response lever (Med Associates). Lever press
responses activated a syringe pump (Med Associates) that delivered 0.1 ml of solution into
the receptacle across a 1.66-s period. Upon and during pump activation, a stimulus light
located above each response lever was illuminated. Any lever press responses during
reinforcer delivery were recorded but produced no programmed consequence. The self-
administration chambers were interfaced (Med Associates) to a computer that was
programmed to control sessions and record data.
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Clear Plexiglas chambers measuring 43.2 × 43.2 cm (Med Associates) were utilized to
assess locomotor activity. The chambers were interfaced to a computer that was
programmed to record the number of photo beam breaks collected over 30 minutes.
Procedure
Prior to the first day of training, water was removed from the home cages for 24 hours. On
the first training session, rats were placed in the self-administration chambers for a 16 hr
shaping session in which the reinforcement schedule increased from a concurrent fixed ratio
one (CONC FR1 FR1) to a CONC FR4 FR4. That is, once 4 reinforcers were delivered on a
lever, the schedule on that lever increased to FR2. Once 10 total reinforcers were received
on that lever, the schedule increased to FR4 (i.e., four lever responses resulted in the
presentation of 0.1 ml of the solution paired with that lever) and that response requirement
remained in effect for the duration of the session. At the end of this session, the rats were
removed from the chambers and returned to their home cage. From this point forward, rats
had access to water ad libitum. After this initial training session, rats were exposed to 30-
minute sessions Monday-Friday on a CONC FR4 schedule of reinforcement in which they
were trained to self-administer ethanol (15% v/v) versus water via a sucrose fading method
(Samson, 1986). This method involved gradually introducing ethanol to the 10% sucrose (w/
v) solution while gradually fading out the sucrose until a 15% (v/v) ethanol solution
maintained responding. The schedule for this method started with 10% sucrose alone then
proceeded as follows: 10% sucrose/2% ethanol (10S/2E), 10S/5E, 10S/10E, 5S/10E, 5S/
15E, 2S/15E. Rats experienced each concentration for two sessions. Following the second
2S/15E session, 15% (v/v) ethanol was maintained for the remainder of the study. Ethanol
was paired with the left lever for half of the rats and with the right lever for the other half of
the rats. After 28 days of baseline training at 15% ethanol vs. water, testing of the
neuroactive steroid compounds began. To habituate the rats to injections, prior to the start of
testing, rats received 3 homecage vehicle injections (SC or IP; depending on group)
approximately 3–4 h after the self-administration sessions.
Testing the effects of ganaxolone and pregnenolone on ethanol self-administration and
locomotor activity
Two groups of rats were administered ganaxolone (0, 1, 3, 10, 20, 30 mg/kg, SC; n=8) or
pregnenolone (0, 10, 20, 50, 75 mg/kg, IP; n=8) and returned to their home cage for 45
minutes. After this interval, the rats were placed in the self-administration chambers for a
30-minute testing session. Doses were administered using a Latin-square design. Each
testing session was preceded by at least two days in which no drug was administered to
allow for baseline level recovery. No tests occurred on Mondays as we usually observe a
trend for higher self-administration on these days. Baseline responding remained stable
between tests.
After completion of the self-administration assessments, the doses found to significantly
alter ethanol self-administration were tested to determine nonspecific motor effects. Rats
from each group were administered ganaxolone (0, 1, 20, 30 mg/kg; n=8) or pregnenolone
(0, 50, 75 mg/kg; n=8) and returned to the home cage for 45 minutes. The rats were then
placed in the locomotor chambers and spontaneous locomotor activity was monitored for
30-minute sessions. Dose order was randomly assigned and each rat experienced three
locomotor sessions. These locomotor sessions were 30 minute in duration to parallel the
self-administration study and were interspersed with self-administration sessions with at
least 2 days between tests. Self-administration sessions were withheld on the locomotor test
days.
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Evaluating the effects of pregnenolone on cortical allopregnanolone levels in ethanol-
experienced and -naïve P rats
The effects of pregnenolone administration on cerebral cortical levels of allopregnanolone
were measured since pregnenolone is a precursor that is known to increase endogenous
levels of GABAergic neuroactive steroids. After the conclusion of the locomotor
assessments, rats experienced standard self-administration sessions for at least 1 month and
then the effects of pregnenolone (50 mg/kg) on allopregnanolone levels in cerebral cortex
were assessed. Rats were injected IP with pregnenolone (n=6) or vehicle (n=5) 45 minutes
prior to brain tissue collection. Rats were not exposed to ethanol self-administration training
on this day. Rats were decapitated and cortices were immediately dissected and placed on
dry ice before storing at −80°C. To determine the effects of pregnenolone in ethanol naïve
animals, a group of naïve P rats was administered pregnenolone (0 or 50 mg/kg, IP; n=7/
dose) 45 minutes prior to sacrifice, and brain tissue was collected as described. A
radioimmunoassay was then used to determine cerebral cortical allopregnanolone levels.
The assay was carried out as previously described in Janis et al. (1998). Briefly, brain
samples were weighed and suspended in 2.5 ml of 0.3N NaOH, homogenized with a sonic
dismembrator and extracted three times with 3 ml aliquots of 10% ethyl acetate in heptane
(v/v). Extraction recovery was monitored by the addition of 2000 cpm of
[3H]allopregnanolone. The brain extracts were purified using solid phase silica columns
(Burdick and Jackson, Muskegon, MI) and subsequently dried. Samples were reconstituted
and assayed in duplicate by the addition of [3H]allopregnanolone and anti-allopregnanolone
polyclonal sheep antibody (Obtained from Dr. Robert Purdy, Scripps Research Institute).
Total binding was determined in the absence of unlabeled allopregnanolone and nonspecific
binding was determined in the absence of antibody. The antibody binding reaction was
allowed to equilibrate for 2 hours and cold dextran-coated charcoal was used to separate
bound from unbound steroid. Bound radioactivity was determined by liquid scintillation
spectroscopy. Steroid levels in the samples were extrapolated from a concurrently run
standard curve and corrected for their respective extraction efficiencies. The inter-assay
coefficient of variation was 9.1% and the intra-assay coefficient of variation is 2.2%. The
allopregnanolone antibody has minimal cross reactivity with other circulating steroids (Janis
et al., 1998), including progesterone < 3%, 3α,5β-THP 6.6%, 3β,5α-THP 2.8%, 3β,5β-THP
0.5%, 5α-pregnan-3α,20α-diol 0.1% and 5α-pregnan-3,20-dione 3.5%. However, the
antiserum cross-reacts with (3α3-hydroxy-4-pregnen-20-one > 100%. This steroid is also a
potent modulator of GABAA receptors (Morrow et al., 1990) and has been found at
comparable levels to allopregnanolone in serum (Wiebe et al., 1994), but at markedly lower
levels than allopregnanolone in cerebral cortex (Griffin and Mellon, 2001).
Drugs
Ethanol (95%) was diluted in distilled water (15% v/v). Ganaxolone (Tocris, Ellisville MO),
and pregnenolone (Steraloids, Newport, RI) were dissolved in 45% w/v 2-hydroxypropyl-β-
cyclodextrin. Ganaxolone and pregnenolone were injected at 2 ml/kg (SC and IP,
respectively) for the self-administration and locomotor experiments. Given that ganaxolone
is identical in structure to allopregnanolone, except for the addition of a 3β-methyl group at
C3 (Carter et al., 1997), the ganaxalone dose range was chosen based on previously
published assessments of allopregnanolone (Finn et al., 2008; Nie and Janak, 2003). The
pregnenolone dose range was selected based on prior work showing an increase in
GABAergic neurosteroids at 50 mg/kg (Porcu et al., 2009). For the experiments measuring
cortical allopregnanolone, pregnenolone was injected at a volume of 1 ml/kg.
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For the self-administration studies, total responses on the ethanol and water levers and
cumulative ethanol and water responses during the 30-minute sessions were analyzed by a
two-way repeated measures analysis of variance (RM ANOVA). Ethanol intake (g/kg) was
estimated from body weight and the number of reinforcers delivered and analyzed by a one-
way RM ANOVA. For the locomotor assessments, total distance traveled in the 30-minute
session was analyzed by a RM ANOVA. Student Newman Keuls’ post hoc comparisons
were used to extract significant main effects and interactions. Statistical significance was
declared at p ≤0.05.
Results
Baseline data (mean ± S.E.M.) were obtained the 2 days prior to the initiation of ganaxolone
testing. Average ethanol lever responses were 149.5 ± 20.1, and average water lever
responses were 6.1 ± 1.8. The baseline total ethanol intake was 0.79 ± 0.08 g/kg.
Ganaxolone produced a biphasic effect on operant responding for ethanol (Figure 1A). The
highest dose of ganaxolone (30 mg/kg) significantly reduced ethanol lever responding
(p<0.001), while the lowest dose of ganaxolone (1 mg/kg) significantly increased ethanol
lever responding (p=0.04). The two-way repeated measures ANOVA showed a significant
main effect of ganaxolone dose (F(4,24)=7.40, p<0.001), a significant main effect of
responses on the ethanol lever (F(1,6)=93.38, p<0.001) and a significant interaction between
dose and ethanol lever responses (F(4,24)=6.69, p<0.001). In contrast, no dose of
ganaxolone significantly affected water lever responding. Ethanol intake (g/kg) was
significantly reduced by ganaxolone pretreatment (Table 1), and there was a trend for an
increase at the lowest ganaxolone dose (1 mg/kg; p=0.08). Although not significant, there
was a trend for reduced ethanol intake (g/kg) after vehicle administration relative to baseline
levels (p=0.09).
Cumulative responses were examined to determine the pattern of ethanol responding across
time (Figure 1B). There was a significant main effect of time (F(5,30)=17.85, p<0.001), a
significant effect of ganaxolone dose (F(4,24)=7.09, p<0.001) and a dose and time
interaction (F(20,120)=3.59, p<0.001). The highest ganaxolone dose (30 mg/kg)
significantly reduced ethanol responding relative to vehicle after 5 minutes of the 30-minute
self-administration session and this reduction continued for the remainder of the session
(ps<0.05). Cumulative water responses were also examined (data not shown). There was a
significant main effect of time on water responding (F(5,30)=5.15, p=0.002), but there was
no significant main effect of ganaxolone dose. A significant interaction between dose and
time existed (F(20,120)=2.28, p=0.003), but there was no significant difference between
dose and vehicle across time according to post hoc tests. Analysis of the locomotor
assessment showed a significant reduction in activity with ganaxolone (30 mg/kg) relative to
vehicle (p<0.001; Figure 1C). Thus, the dose that significantly decreased ethanol self-
administration (30 mg/kg) also produced a motor impairment in treated rats.
Baseline (2 days prior to the initiation of pregnenolone testing) ethanol lever responses were
147.8 ± 12.8, and average water lever responses were 14.2 ± 2.1. The baseline total ethanol
intake was 0.84 ± 0.07 g/kg. Pregnenolone significantly reduced ethanol self-administration
(Figure 2A). The two-way RM ANOVA showed a significant main effect of pregnenolone
dose (F(4,20)=5.05, p=0.006), a significant main effect of responses on the ethanol lever
(F(1,5)=46.24, p=0.001), and a significant interaction (F(4,20)=3.79, p=0.019). The post hoc
comparisons indicated that 75 mg/kg (p<0.001) and 50 mg/kg (p=0.003) pregnenolone
reduced total session ethanol (15%, v/v) reinforced responding relative to vehicle. Ethanol
intake (g/kg) was significantly reduced by pregnenolone administration (75 mg/kg; Table 1).
Ethanol intake after vehicle administration did not differ from the baseline value.
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Examination of the cumulative ethanol responses showed a significant effect of time
(F(5,25)=24.12, p<0.001), a significant effect of pregnanolone dose (F(4,20)=5.57,
p=0.004), and a significant interaction (F(20,100)=2.03, p=0.011). Post hoc analysis
indicated a significant reduction of ethanol responses after pregnenolone (50 and 75 mg/kg)
pretreatment relative to vehicle after the first 5 minutes of the session and continuing for the
remainder of the session (ps<0.05; Figure 2B). Cumulative water responding was not
significantly affected by pregnenolone dose (F(4,20)=2.63, p=0.07), but was affected by
time (F(5,25)=9.14, p<0.001). However, a significant interaction did exist between dose and
time (F(20,100)=1.79, p=0.03). Water responding after administration of pregnenolone (75
mg/kg) differed from vehicle at the end of the 30-minute session (p=0.03). Analysis of the
locomotor data showed there were no significant nonspecific motor effects following
pregnenolone pretreatment (0, 50, 75 mg/kg; Figure 2C).
In ethanol-naïve P rats, pregnenolone treatment did not produce a significant increase in
cortical allopregnanolone levels (p=0.16). In contrast, in ethanol-experienced P rats (i.e., the
self-administration trained animals) pregnenolone administration significantly increased
cortical allopregnanolone levels as compared to vehicle (p=0.004; Fig. 3).
Discussion
The goal of the present work was to examine the effects of the neuroactive steroids
ganaxalone and pregnenolone on ethanol reinforcement in the alcohol-preferring P rat line, a
genetic model of excessive alcohol drinking (Murphy et al., 2002). Indeed, ethanol intake in
this study (after vehicle administration) ranged from 0.4 – 1.1 g/kg during the 30-minute
sessions, which overlaps with the range we have previously reported corresponds to blood
ethanol levels of approximately 80 mg/dl (Besheer et al., 2008). The results from this study
show that ganaxalone administration produced a dose-dependent biphasic effect on operant
ethanol self-administration. The lowest dose of 1 mg/kg increased ethanol reinforced
responding, but the dose of 30 mg/kg significantly reduced ethanol reinforced responding.
However the ganaxalone-induced reductions in ethanol self-administration may have been
related to nonspecific reductions in motor activity. In contrast, pregnenolone administration
reduced operant ethanol self-administration in the absence of nonspecific motor effects on
motor activity. These results indicate that elevating pregnenolone may be an effective
mechanism by which to reduce ethanol self-administration.
Previous work has shown neuroactive steroid modulation of ethanol drinking using two-
bottle choice procedures and operant ethanol self-administration, with both increases and
decreases in drinking reported (Ford et al., 2008a; Janak and Michael Gill, 2003; Janak et
al., 1998; Morrow et al., 2001; O’Dell et al., 2005; Sinnott et al., 2002b). In the present
study, pretreatment with the long-acting synthetic neuroactive steroid ganaxalone produced
a bidirectional effect on ethanol-reinforced responding. At the lowest ganaxolone dose
tested (1 mg/kg) total session responding on the ethanol lever was increased but ethanol
intake (g/kg) showed only a trend, perhaps due to minor variations in body weight and
number of ethanol reinforcers. The increase in responding was unrelated to motor activity as
shown by the lack of effect of this ganaxalone dose on water responding and in the
locomotor assessment. This finding of increased ethanol-reinforced responding has also
been demonstrated after pretreatment with allopregnanolone, and like ganaxolone,
allopregnanolone had biphasic effects (Janak et al., 1998) and reduced ethanol responding at
higher doses (Ford et al., 2007). This result is also consistent with previous work showing
that the long-acting non-hydrolyzable GABAergic neuroactive steroid 3α,5β-20-oxo-
pregnane-3-carboxylic acid (PCA) reduces total session ethanol self-administration in
Wistar rats (O’Dell et al., 2005). Thus, it appears that both short and long acting neuroactive
steroids have similar biphasic effects on ethanol-reinforced responding. However, given that
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ganaxolone also significantly suppressed spontaneous motor activity at the dose which
reduced ethanol intake, it is possible that the reductions in self-administration were
associated with nonspecific motor reductions. Indeed, high doses of allopregnanolone have
been previously shown to reduce spontaneous locomotor activity (Wieland et al., 1995).
Thus, given the associated motor impairment, it is premature to conclude that ganaxolone
specifically reduces ethanol reinforcement. Ganaxolone has previously been shown to
produce sedation that diminishes with chronic exposure (Nohria and Giller, 2007).
Additional studies are needed to determine if the ganaxolone-induced reduction in ethanol
responding and intake would show tolerance after chronic exposure.
The increase in ethanol-reinforced responding after administration of the low dose of
ganaxolone suggests an increase in the reinforcing function of ethanol. Indeed,
allopregnanolone has been shown to have reinforcing effects as rats display preference for
orally consumed allopregnanolone over water in a two-bottle choice procedure (Sinnott et
al., 2002a) and allopregnanolone can condition a place preference (Finn et al., 1997). A
possible behavioral mechanism underlying the ganaxolone-induced increase in responding
for ethanol in the present work may be related to drug priming. That is, a priming injection
of the self-administered drug can increase drug-seeking behavior (de Wit and Stewart,
1981). An interpretation of this effect is that the stimulus properties of the self-administered
drug have acquired control over behavior during self-administration training, and thus a drug
with similar pharmacological properties would also promote drug-seeking behavior (de Wit
and Stewart, 1981). Consistent with this explanation, is the finding that allopregnanolone
can reinstate ethanol-seeking behavior (Finn et al., 2008; Nie and Janak, 2003), and that
allopregnanolone has ethanol-like discriminative stimulus effects (Bowen et al., 1999; Grant
et al., 1996; Hodge et al., 2001). Thus, it is possible that the low ganaxolone dose has
ethanol-like effects that served as a priming cue to increase operant responding for ethanol,
although ethanol intake was not enhanced. Interestingly, an increase in ethanol-reinforced
responding was not evident after pregnenolone treatment in the present work. It is possible
that a lower pregnenolone dose range than the one tested in the present study may enhance
self-administration. This will be an interesting possibility to address in future work.
Ethanol self-administration was also significantly reduced by pregnenolone treatment. To
assess the effects of pregnenolone over time, the pattern of responding was examined.
Pregnenolone treatment at the two highest doses (50 and 75 mg/kg) suppressed ethanol
responding throughout the 30-minute session, suggesting that pregnenolone effects were
sustained for the duration of the session. This data pattern also suggests that the
pregnenolone-induced reductions were likely not due to a pharmacological interaction with
the consumed ethanol given that this pattern of responding resulted in little ethanol delivery.
In contrast to the motor-impairing effects of the highest dose of ganaxolone, the locomotor
assessment following pregnenolone administration showed no significant reduction in motor
activity at the same doses that reduced ethanol self-administration, suggesting that
suppression of self-administration was not related to nonspecific effects on motor activity.
However, given that the highest pregnenolone dose (75 mg/kg) produced a significant
reduction in cumulative water responses by the end of the self-administration session, a non-
specific motor impairment at this dose cannot be entirely dismissed. Together these results
suggest a selective role of the neuroactive steroid pregnenolone, but not ganaxolone in the
reduction of ethanol self-administration.
Pregnenolone is the precursor of numerous steroid hormones. It is converted into
progesterone and then deoxycorticosterone, precursors of the potent GABAA receptor
positive modulators, such as allopregnanolone, 3α,5β-THP, and 3α,5α-THDOC. Previous
work has determined a role for GABAergic systems in the modulation of ethanol
reinforcement and drinking behavior (Besheer et al., 2006; Boyle et al., 1993; Hodge et al.,
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1995; Hodge et al., 1996; McBride et al., 1988; Rassnick et al., 1993; Roberts et al., 1996),
and the pregnenolone-induced reductions in self-administration may be related to increased
activity of the GABAergic neuroactive steroids. However, pregnenolone is also the
precursor of glucocorticoids (cortisol in humans and corticosterone in rodents), which have
the potential to affect ethanol drinking (Chester et al., 2006; Lynch et al., 1999; Vengeliene
et al., 2003; Volpicelli et al., 1990). Finally, the sulfated derivative of pregnenolone inhibits
GABAA receptor function (Carette and Poulain, 1984; Majewska and Schwartz, 1987) and
positively modulates NMDA receptors (Bowlby, 1993; Irwin et al., 1994; Wu et al., 1991),
albeit at high micromolar concentrations and only when applied in vitro. Given its
widespread actions, it will be interesting to determine the specific mechanism(s) modulating
the pregnenolone-induced reduction in ethanol self-administration in future studies.
Previous studies have shown that GABAergic neuroactive steroids decrease ethanol self-
administration and drinking (Janak et al., 1998; Martin-Garcia et al., 2007; Morrow et al.,
2001; O’Dell et al., 2005), consistent with the decreased self-administration observed after
pregnenolone administration in the present work. Further, given that allopregnanolone is a
metabolite of pregnenolone, we sought to determine whether pregnenolone elevates
allopregnanolone levels in P rats. Indeed, cerebral cortical allopregnanolone levels after
pregnenolone administration showed a significant increase in the ethanol-experienced P rats
(i.e., self-administration trained), but not in the ethanol naïve P rats. This increased
sensitivity to pregnenolone administration in animals with a history of ethanol self-
administration suggests the possibility of adaptations in neuroactive steroid biosynthesis.
This result also suggests that the decrease in ethanol self-administration after pregnenolone
administration may be related, in part, to increased levels of allopregnanolone.
In conclusion, results from the present work suggest that pregnenolone may be a novel
therapeutic for reducing chronic ethanol drinking. An advantage to the utilization of this
compound is that it has been used in various clinical populations and appears to be generally
well tolerated with a positive safety profile (Freeman et al., 1950; Guest et al., 1950; Marx et
al., 2009; Meieran et al., 2004). Further, recent work in schizophrenic patients showed that
pregnenolone serum levels after pregnenolone administration were positively correlated with
cognitive improvements (Marx et al., 2009). Evidence for cognitive improvements is
significant given that cognitive deficits are common in alcohol dependent individuals (Fein
et al., 1990; Pitel et al., 2007) and may interfere with effective therapy (Bates et al., 2006).
Clearly, future work will need to elucidate the mechanism(s) by which pregnenolone affects
alcohol drinking; however, the novel findings of this work suggest that pregnenolone may
be a viable compound for reducing chronic alcohol drinking.
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Panel A. Mean (±SEM) total ethanol (15% v/v) and water responses 45 minutes after
pregnenolone (0, 10, 20, 50, 75 mg/kg, IP; n=8) administration. Panel B. Mean (±SEM)
cumulative ethanol responses over 30-minute self-administration testing session 45 minutes
after pregnenolone pretreatment (n=8). Panel C. Mean (±SEM) total distance traveled (cm)
45 minutes after pregnenolone treatment (0, 50, 75 mg/kg, IP; n=8). *Notes a significant
difference from vehicle (Student-Newman-Keuls’ post hoc test, p<0.05).
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Panel A. Mean (±SEM) total ethanol (15% v/v) and water responses 45 minutes after
ganaxolone (0, 1, 3, 10, 30 mg/kg, SC; n=8) injection. Panel B. Mean (±SEM) cumulative
ethanol responses over a 30-minute self-administration session following a 45 minute
ganaxolone pretreatment (n=8). Panel C. Mean (±SEM) total distance traveled (cm) 45
minutes after ganaxolone pretreatment (0, 1, 3, 10, 30 mg/kg, SC; n=8). *Notes a significant
difference from vehicle (Student-Newman-Keuls’ post hoc test, p<0.05).
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Mean (±SEM) cortical allopregnanolone (ng/g) levels in ethanol-experienced (i.e., self-
administration trained) and ethanol-naïve P rats determined after a 45-minute pregnenolone
(0, 50 mg/kg, IP; n=5, n=6, respectively) pretreatment (t-test, p<0.05).
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Table 1
Ethanol intake (g/kg) after ganaxolone and pregnenolone administration (mean ± SEM)
Ganaxolone dose (mg/kg, SC)
0 1 3 10 30
0.55 ± 0.08 0.89 ± 0.11 0.69 ± 0.12 0.38 ± 0.10 0.07 ± 0.06*
Pregnenolone dose (mg/kg, IP)
0 10 20 50 75
0.72 ± 0.11 0.71 ± 0.12 0.57 ± 0.09 0.33 ± 0.04 0.20 ± 0.12*
*
p<0.05 relative to 0 (Student Newman Keuls’ post hoc test)
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